A Pipeline Built With Purpose
Leading with science and compassion, our team purposefully builds our pipeline to improve patients’ lives, relentlessly pushing science forward by creatively investigating pathways to reveal uncharted scientific discoveries and deliver transformational medicines.
- Phase 1
- Phase 2
- Phase 3
A humanized, affinity-optimized, afucosylated IgG1 kappa (IgG1κ) monoclonal antibody (mAb) that binds to the B cell-specific surface antigen CD19.
IgG4-Related Disease: Phase 3 trial evaluating UPLIZNA for the prevention of flare in patients with IgG4-related disease.
Myasthenia Gravis (MINT): Phase 3 trial evaluating UPLIZNA for improving outcomes in patients with myasthenia gravis.
Diffuse Cutaneous Systemic Sclerosis
Idiopathic Pulmonary Fibrosis
A molecule that blocks lysophosphatidic acid receptor 1 (LPAR1). We are conducting a Phase 2b pivotal trial in diffuse cutaneous systemic sclerosis and a Phase 2b pivotal trial in idiopathic pulmonary fibrosis.
Learn more about the HZN-825 trial in idiopathic pulmonary fibrosis here.
Learn more about the HZN-825 trial in diffuse cutaneous systemic sclerosis here.
Focal Segmental Glomerulosclerosis
Kidney Transplant Rejection
Discoid Lupus Erythematosus
Systemic Lupus Erythematosus
TED in Japan (OPTIC-J)
Diffuse Cutaneous Systemic Sclerosis
A monoclonal antibody against insulin-like growth factor-1 receptor (IGF-1R).
TED in Japan (OPTIC-J): Phase 3 randomized, placebo-controlled trial in Japan to evaluate TEPEZZA in patients with moderate-to-severe active TED.
Diffuse Cutaneous Systemic Sclerosis: Phase 1 trial exploring TEPEZZA in diffuse cutaneous systemic sclerosis.
Subcutaneous Administration: Phase 1 pharmacokinetic trial to explore subcutaneous administration of TEPEZZA.
A fully human monoclonal antibody that binds and neutralizes the function of the FLT3-ligand, thereby reducing both conventional and plasmacytoid dendritic cells. We are conducting a Phase 1 trial in autoimmune diseases.
Additional Autoimmune Disease
Collaboration and option agreement with Q32 Bio to develop ADX-914, a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function by blocking signaling mediated by both IL-7 and TSLP, two key immune pathways.
Atopic Dermatitis: Phase 2 trial being conducted by Q32 Bio to evaluate ADX-914 in atopic dermatitis.
Additional Autoimmune Disease: Phase 2 trial to be conducted by Q32 Bio to evaluate ADX-914 in a second autoimmune disease.
Horizon has an option to acquire ADX-914 from Q32 Bio on pre-negotiated terms through the completion of Phase 2 clinical trials.
Exclusive collaboration to develop novel, multi-specific fusion protein based therapies for autoimmune and inflammatory diseases.
Next-Gen Uncontrolled Gout
Exclusive collaboration to investigate a short interfering RNA (siRNA) therapeutic targeting xanthine dehydrogenase in the liver (GalNAc) to reduce serum uric acid and treat uncontrolled gout.
Novel Gout Targets
Exclusive collaboration to discover new therapeutics for novel gout targets by combining HemoShear’s discovery expertise with Horizon’s rheumatology development and commercialization expertise.
Moving On-Market Medicines Forward
Horizon is exploring the potential of its on-market medicines to identify paths for new treatment methods and improve patient outcomes.
A recombinant uricase enzyme that breaks down uric acid.
AGILE: Phase 4 trial evaluating the impact of administering KRYSTEXXA over a shorter infusion duration in patients with uncontrolled gout who are receiving methotrexate.
FORWARD OL: Phase 4 trial evaluating monthly dosing of KRYSTEXXA with methotrexate in patients with uncontrolled gout.
Clinical trials are essential to the research and development process and play a vital role in helping physicians and investigators understand how an investigational medicine may safely and effectively treat a specific disease or condition.
For a comprehensive list of current clinical trials involving Horizon medicines, please visit: www.clinicaltrials.gov.
For more information about expanded access programs, read our Expanded Access Policy Statement.
This information was last updated on November 2, 2022.